Literature DB >> 28547724

Costs associated with community acquired pneumonia in France.

Grèce Saba1, Luiz Flavio Andrade2, Jacques Gaillat3, Pierre Bonnin3, Christian Chidiac4, Hajnal-Gabriela Illes5, Henri Laurichesse5, Jonathan Messika6,7,8, Jean-Damien Ricard6,7,8, Bruno Detournay9, Patrick Petitpretz10, Gérard de Pouvourville11.   

Abstract

OBJECTIVES: Pneumocost is a prospective study that aimed at documenting the costs of the management of patients hospitalized with a pneumococcal pneumonia and the post-discharge costs during a 6-month period in the French context.
METHODS: Billing data were used to document hospital costs. Resource use during the follow-up period was collected through phone interviews at month 1, 3 and 6. Descriptive statistics and multivariate analyses were performed. We used generalized linear models with log-link functions to estimate parameters associated with hospital and follow-up costs of patients.
RESULTS: Five hundred twenty-four patients were enrolled in 40 public centers from October 2011 to April 2014. Average age was 63 (SD 17); 55.0% of them were male. Average length of stay was 15 days (SD 23). Average cost of stay for the French Sickness Fund was €7293 (SD €7363). Average cost of follow-up was €1242 (SD €3000) and decreased steadily through time. When controlling for patient's socioeconomic characteristics, severity of disease and hospital stay, results showed a concave relationship between hospital costs and age. Obesity, the severity of the disease and comorbidities were associated with constantly increasing inpatient costs. Concerning follow-up costs, we found the same concave relationship with age, while gender, a history of pneumonia and severity of the disease were the most important predictors of high costs after discharge.
CONCLUSION: Pneumocost is the first French study providing a robust estimation of the cost of managing invasive pneumococcal pneumonia in the French context.

Entities:  

Keywords:  Cost study; France; Pneumococcal pneumonia

Mesh:

Year:  2017        PMID: 28547724     DOI: 10.1007/s10198-017-0900-z

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  23 in total

1.  Predicting mortality in the elderly with community-acquired pneumonia: should we design a new car or set a new 'speed limit'?

Authors:  Veronica Brito; Michael S Niederman
Journal:  Thorax       Date:  2010-11       Impact factor: 9.139

2.  Decrease in long-term survival for hospitalized patients with community-acquired pneumonia.

Authors:  Jose Bordon; Timothy Wiemken; Paula Peyrani; Maria Luz Paz; Martin Gnoni; Patricio Cabral; Maria del Carmen Venero; Julio Ramirez
Journal:  Chest       Date:  2010-04-09       Impact factor: 9.410

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

Authors:  Sara Boccalini; Angela Bechini; Miriam Levi; Emila Tiscione; Roberto Gasparini; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

5.  Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.

Authors:  A Ament; R Baltussen; G Duru; C Rigaud-Bully; D de Graeve; A Ortqvist; B Jönsson; J Verhaegen; J Gaillat; P Christie; A S Cifre; D Vivas; C Loiseau; D S Fedson
Journal:  Clin Infect Dis       Date:  2000-09-05       Impact factor: 9.079

6.  Longitudinal DRG-based survey of all-cause and pneumococcal pneumonia and meningitis for inpatients in France (2005-2010).

Authors:  P Casez; J Fauconnier; L Jorgensen; E M Gutterman; S Gray; S Munson; N Dartois; J Gaillat
Journal:  Med Mal Infect       Date:  2015-11-20       Impact factor: 2.152

7.  Incidence and cost of CAP in a large working-age population.

Authors:  Machaon M Bonafede; Jose A Suaya; Kathleen L Wilson; David M Mannino; Daniel Polsky
Journal:  Am J Manag Care       Date:  2012-07       Impact factor: 2.229

8.  Hospitalization costs for community-acquired pneumonia in Dutch elderly: an observational study.

Authors:  Conrad E Vissink; Susanne M Huijts; G Ardine de Wit; Marc J M Bonten; Marie-Josée J Mangen
Journal:  BMC Infect Dis       Date:  2016-09-02       Impact factor: 3.090

9.  Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50 years.

Authors:  Reiko Sato; Gabriel Gomez Rey; Stephanie Nelson; Brett Pinsky
Journal:  Appl Health Econ Health Policy       Date:  2013-06       Impact factor: 2.561

10.  Increasing hospital admissions for pneumonia, England.

Authors:  Caroline L Trotter; James M Stuart; Robert George; Elizabeth Miller
Journal:  Emerg Infect Dis       Date:  2008-05       Impact factor: 6.883

View more
  4 in total

1.  Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium.

Authors:  Lander Willem; Adriaan Blommaert; Germaine Hanquet; Nancy Thiry; Joke Bilcke; Heidi Theeten; Jan Verhaegen; Herman Goossens; Philippe Beutels
Journal:  Hum Vaccin Immunother       Date:  2018-02-22       Impact factor: 3.452

2.  Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs.

Authors:  Claire Dupuis; Ayman Sabra; Juliette Patrier; Gwendoline Chaize; Amine Saighi; Céline Féger; Alexandre Vainchtock; Jacques Gaillat; Jean-François Timsit
Journal:  Crit Care       Date:  2021-01-10       Impact factor: 9.097

3.  The 13-Valent Pneumococcal Conjugate Vaccine Elicits Serological Response and Lasting Protection in Selected Patients With Primary Humoral Immunodeficiency.

Authors:  Ailsa Robbins; Mathilde Bahuaud; Maxime Hentzien; Quentin Maestraggi; Coralie Barbe; Delphine Giusti; Richard Le Naour; Frederic Batteux; Amélie Servettaz
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

4.  Health related quality of life in patients with community-acquired pneumococcal pneumonia in France.

Authors:  Luiz Flavio Andrade; Grèce Saba; Jean-Damien Ricard; Jonathan Messika; Jacques Gaillat; Pierre Bonnin; Christian Chidiac; Hajnal-Gabriela Illes; Henri Laurichesse; Bruno Detournay; Patrick Petitpretz; Gérard de Pouvourville
Journal:  Health Qual Life Outcomes       Date:  2018-02-02       Impact factor: 3.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.